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This issue features articles related to endocrine andmetabolic
regulation in cancer and diabetes. The modern diet, rich in
fat and refined carbohydrates, is creating worldwide obesity
and diabetes epidemics. As early as 1959, Joslin and colleagues
speculated about an association between diabetes and cancer,
and current epidemiologic evidence indicates an increased
risk of various types of cancer, with increased morbidity,
in diabetes patients. The underlying mechanisms for this
association have not been fully elucidated as yet.
Cancer, diabetes, and obesity are all chronic diseases
with common discernible alterations in metabolic processes.
A sweet tooth and alterations in the glucose metabolism
are common underlying themes. As scientists uncover more
evidence to support this idea, the current research focuses on
preventative strategies and treatments targeting disturbances
in common cellular metabolic pathways. Some of the drugs
used clinically to treat diabetes have been shown to have
antitumour effects, as highlighted in the review of N. Turner
et al. (University of New South Wales, Australia).
However, targeted treatments are not so easily imple-
mented and have some inherent complexities, which derive
from the possibility that some diabetes treatments may alter
cancer risk. Alternatively, some cancer treatments may be
incompatible with diabetes therapies.Thiazolidinediones and
metformin are two common diabetes treatments which show
promise as cancer therapeutics. In this edition, E. Fro¨hlich
and R. Wahl (University of Tuebingen, Germany) discuss
thiazolidinediones as treatments for multiple cancer types
whilst the review by D. Hatoum and E. M. McGowan
(University of Technology Sydney, Australia) summarizes
recent advances in the use of metformin in comorbidity of
diabetes and breast cancer. Although the in vitro evidence is
compelling, retrospective evidence for comorbidity therapy
is controversial. As another option, contemporary research
directed at targeting the sphingolipid rheostat holds great
promise for diabetes and cancer therapy. The paper by K.
Marzec et al. (Kolling Institute, Sydney, Australia) strongly
supports a role for targeting sphingosine kinase 1 (SphK1) in
combinational treatments for the hard tomanage triple nega-
tive breast cancers (TNBC), whereas the corresponding paper
by N. K. Haass et al. (University of Queensland/University of
Technology Sydney, Australia) focuses on the complexities
inherent in the use of sphingosine kinase/sphingosine-1-
phosphate modulators in the treatment of comorbidity of
cancer and diabetes.
It is becoming clear that obesity and cancer is not a ran-
dom association. A. J. Hoy et al. (University of Sydney, Aus-
tralia) emphasize that key pathways of fatty acid metabolism
are altered in cancer. Associations between obesity, ovarian
steroid hormones, and cancer are common themes in two
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complementary papers by V. Boonyaratanakornkit and P.
Pateetin (Chulalongkorn University, Thailand) and K. H.
Joung et al. (Chungnam National School of Medicine, North
Korea).These papers describe the strong prevalence of cancer
in postmenopausal obese women. V. Boonyaratanakornkit
and P. Pateetin raise the importance of developing a bet-
ter understanding of the molecular mechanisms and sig-
nalling pathways associated with alterations in endocrine and
metabolic regulation in obese women for improved breast
cancer treatment.
IGF-1 and insulin are strongly associated with most
diabetes related cancers. Several of the papers in this issue
focus on the importance of the insulin-like growth factors
(IGFs) as novel targets for cancer therapies. K. Marzec et al.
concentrate on IGF binding protein 3 (IGFP-3) as a critical
target for TNBCs. The original paper authored by the R.
Pietras group (UCLA, USA) showed that elevated IGF-2 was
concomitant with stimulated estrogen receptor-𝛽 (ER𝛽) and
poor overall survival. Furthermore, the paper by H. S. Atreya
et al. (Indian Institute of Science, India) advanced the concept
of blocking IGF and IGFBPs in cancer therapies.
The scope of this special issue highlights the growing
awareness of the link between altered cellularmetabolism and
the risk of developing diabetes and cancer. Understanding
and targeting altered cellular metabolism in individuals with
or without diabetes, so as to reduce the risk of developing
cancer, form the basis for future combinational treatments.
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